secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001683168-23-005094
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio shareholders approve incentive plan amendment, adding 125,500 shares
-------------------------------------------------------------------------

- At July 20, 2023 annual meeting, shareholders approved amendment to 2020 Long Term Incentive Plan.
- Plan shares increased by 125,500 to a total of 225,500 shares available for issuance.
- All five director nominees elected: Bitterman, Bradford, Ferrara, Freeman, Lockshin.
- BDO USA LLP ratified as independent auditor for FY 2023 with 605,026 for, 21,903 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer